Charles Sternberg, Assistant Editor04.23.21
Johnson & Johnson has shared results for first-quarter 2021.
Reported sales for the quarter were $22,321 million, up 7.9% compared to 2020.
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9% primarily driven by negative prior year comparisons related to the Covid-19 pantry loading in Q1 2020, mainly in over-the counter products. Partially offsetting the decline is growth in Listerine in oral care products and Johnson’s Baby in baby care products, international skin health/beauty products.
“The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere,” said Alex Gorsky, chairman and CEO.
Reported sales for the quarter were $22,321 million, up 7.9% compared to 2020.
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9% primarily driven by negative prior year comparisons related to the Covid-19 pantry loading in Q1 2020, mainly in over-the counter products. Partially offsetting the decline is growth in Listerine in oral care products and Johnson’s Baby in baby care products, international skin health/beauty products.
“The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere,” said Alex Gorsky, chairman and CEO.
